| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Infigratinib phosphate (USAN); Truseltiq (TN) | ||||||
| Product | TRUSELTIQ (QED Therapeutics) | ||||||
| Formula | C26H31Cl2N7O3. H3PO4 | ||||||
| Exact mass | 657.1634 | ||||||
| Mol weight | 658.4706 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03208 FGFR inhibitor | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, Angiogenesis inhibitor | ||||||
| Disease | Cholangiocarcinoma (FGFR2 fusion or other rearrangement) [DS:H00046] | ||||||
| Target | FGFR2* (CD332) [HSA_VAR:2263v2 2263v1] [HSA:2263] [KO:K05093] FGFR1 (CD331) [HSA:2260] [KO:K04362] FGFR3 (CD333) [HSA:2261] [KO:K05094] | ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors L01EN03 Infigratinib D11611 Infigratinib phosphate (USAN) <US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Infigratinib D11611 Infigratinib phosphate (USAN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03208 FGFR inhibitor DG03062 Infigratinib D11611 Infigratinib phosphate Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) FGFR family FGFR1 (CD331) D11611 Infigratinib phosphate (USAN) <US> FGFR2* (CD332) [HSA_VAR:2263v2 2263v1] D11611 Infigratinib phosphate (USAN) <US> FGFR3 (CD333) D11611 Infigratinib phosphate (USAN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11611 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11611 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D11611 Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03208 FGFR inhibitor DG03062 Infigratinib | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 43 1 N1y N 9.6102 -13.7182 2 C1x C 9.6102 -15.1806 3 C1x C 10.8636 -15.8769 4 N1y N 12.0474 -15.1806 5 C1x C 12.0474 -13.7182 6 C1x C 10.8636 -13.0219 7 C1b C 8.4264 -13.0219 8 C1a C 7.2427 -13.7182 9 C8y C 13.2312 -15.8769 10 C8x C 13.2312 -17.2696 11 C8x C 14.4846 -17.9659 12 C8y C 15.6684 -17.2696 13 C8x C 15.6684 -15.8769 14 C8x C 14.4846 -15.1806 15 N1b N 16.9218 -17.9659 16 C8y C 18.1055 -17.2696 17 C8x C 19.2893 -17.9659 18 C8y C 20.4731 -17.2696 19 N5x N 20.4731 -15.8073 20 C8x C 19.2893 -15.1806 21 N5x N 18.1055 -15.8769 22 N1c N 21.7265 -17.9659 23 C5a C 22.9103 -17.2696 24 C1a C 21.7265 -19.3586 25 N1b N 24.0941 -17.9659 26 O5a O 22.9103 -15.8769 27 C8y C 25.2778 -17.2696 28 C8y C 26.4616 -17.9659 29 C8y C 27.6454 -17.2696 30 C8x C 27.6454 -15.8073 31 C8y C 26.4616 -15.1806 32 C8y C 25.2778 -15.8769 33 X Cl 26.4616 -19.3586 34 O2a O 26.4616 -13.7182 35 C1a C 27.7150 -13.0219 36 O2a O 28.8988 -17.9659 37 C1a C 30.0826 -17.2696 38 X Cl 24.0244 -15.1109 39 P1b P 34.9300 -17.2200 40 O1c O 34.9300 -15.8200 41 O1c O 33.5300 -17.2200 42 O1c O 36.3300 -17.2200 43 O1c O 34.9300 -18.6200 BOND 45 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 1 7 1 8 7 8 1 9 4 9 1 10 9 10 2 11 10 11 1 12 11 12 2 13 12 13 1 14 13 14 2 15 9 14 1 16 12 15 1 17 15 16 1 18 16 17 2 19 17 18 1 20 18 19 2 21 19 20 1 22 20 21 2 23 16 21 1 24 18 22 1 25 22 23 1 26 22 24 1 27 23 25 1 28 23 26 2 29 25 27 1 30 27 28 2 31 28 29 1 32 29 30 2 33 30 31 1 34 31 32 2 35 27 32 1 36 28 33 1 37 31 34 1 38 34 35 1 39 29 36 1 40 36 37 1 41 32 38 1 42 39 40 2 43 39 41 1 44 39 42 1 45 39 43 1 |